Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Has reproduction · 74
ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia.
PMID 22955991 · PMC3431496 · Genome research · 2012 · 8 claims · 8 setups
ENCODE/modENCODE define a set of working standards and guidelines for ChIP-seq covering antibody validation, experimental replication, sequencing depth, data/metadata reporting, and data quality assessment.
-
Full-text index only
Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers.
PMID 16417627 · PMC1382246 · BMC genetics · 2006 · 8 claims · 7 setups
Heterozygous truncating BRCA2 mutations occur in 47% (7/15) of gastrointestinal MSI cancer cell lines/xenografts, a higher rate than previously reported
-
Full-text index only
Alternative polyadenylation of cyclooxygenase-2.
PMID 15872218 · PMC1088970 · Nucleic acids research · 2005 · 8 claims · 5 setups
The human COX-2 gene undergoes alternative polyadenylation using proximal and distal polyadenylation signals
-
Full-text index only
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.
PMID 18397877 · PMC2427143 · Human molecular genetics · 2008 · 8 claims · 8 setups
All six somatic TSC1 missense mutations found in bladder tumours cause loss of TSC1 function, but via distinct molecular mechanisms.
-
Has reproduction
CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.
PMID 31365872 · PMC6684324 · Cell reports · 2019 · 8 claims · 8 setups
Genome-wide CRISPR/Cas9 screens in CD40L-stimulated Daudi B cells identify known CD40/NF-κB pathway components plus many novel positive and negative CD40 regulators.
-
Has reproduction · 73
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
PMID 39820365 · PMC11739599 · Nature communications · 2025 · 8 claims · 8 setups
RSK1 is a conserved, exploitable therapeutic dependency across MPN and secondary AML
-
Full-text index only
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.
PMID 17540169 · PMC4647864 · Cell · 2007 · 8 claims · 13 setups
DAPK1 promoter is epigenetically silenced by DNA methylation in almost all sporadic CLL cases
-
Full-text index only
Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer.
PMID 18615426 · PMC2992687 · Proteomics · 2008 · 8 claims · 6 setups
RPPA-measured CA19-9 levels correlate strongly with ELISA-measured levels in the same patient samples
-
Full-text index only
The malaria secretome: from algorithms to essential function in blood stage infection.
PMID 18551176 · PMC2408878 · PLoS pathogens · 2008 · 8 claims · 5 setups
An expanded secretome (van Ooij secretome) built from a revised SignalP MaxS cutoff (0.571) plus HMMER-expanded HT-motif search yields 422 proteins (224 excluding RIFIN/STEVOR families).
-
Full-text index only
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.
PMID 19936259 · PMC2775948 · PloS one · 2009 · 8 claims · 8 setups
Integrated proteomic analysis of a cancer mouse model and human cancer cell populations provides an effective approach to identify potential circulating protein biomarkers.
-
Full-text index only
Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.
PMID 19888321 · PMC2765613 · PloS one · 2009 · 8 claims · 8 setups
Serum S100A6 concentration correlates with peritoneal tumor burden in a mouse OVCA xenograft model, based on inverse regression calibration against bioluminescent imaging data.
-
Full-text index only
Proteomic and genetic approaches identify Syk as an AML target.
PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups
EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism
-
Full-text index only
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
PMID 18923525 · PMC2587486 · Nature · 2008 · 8 claims · 8 setups
Non-synonymous ALK kinase domain mutations occur in 8% of primary neuroblastomas, with F1174L being the most frequent